Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide or azacitidine in persons $\geq 65$ years with newly-diagnosed acute myeloid leukemia

Bruno C. Medeiros, Kelly McCaul, Suman Kambhampati, Daniel A. Pollyea, Rajat Kumar, Lewis R. Silverman, Andrea Kew, Lalit Saini, C L Beach, Ravi Vij, Xiwei Wang, Jim Zhong, and Robert Peter Gale

Disclosures: BCM has consulted, participated in advisory boards, and received research funding from Celgene Corporation. KM, SK, LS have nothing to disclose. DAP received research funding from Agios Pharmaceuticals, Inc., and participated in advisory boards for Pfizer, Curis, Takeda, Servier, Celgene Corporation, Jazz, Gilead, Pharmacypcics and Alexion. RK participated in advisory boards and received honorarium from Celgene Corporation. LRS has consulted for Celgene Corporation. AK participated in advisory boards and received honoraria from Celgene Corporation, Amgen, Novartis and Janssen. CLB, XW, JZ are employed and have equity ownership in Celgene Corporation. RV has consulted and received honoraria from Amgen, Takeda, Celgene Corporation, BMS, Janssen, Abbvie, and Karyopharma; received research support from Amgen and Takeda. RPG is a part-time employee and has equity ownership in Celgene Corporation.

Contributions: BCM, CLB, RPG designed the study; BCM and RPG developed the first draft; RV, XW, and JZ compiled data and performed statistical analyses, BCM, CLB, RPG, KMcc, SK, DAP, RK, LRS, AK, and LS edited and revised all draft versions. The authors are responsible for all content and editorial decisions.